Nascent Biotech (NBIO) 10-K 12 Jul 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2019	Jul. 12, 2019	Sep. 30, 2018
Document And Entity Information
Entity Registrant Name	NASCENT BIOTECH INC.
Entity Central Index Key	0001622057
Document Type	10-K
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		33,495,470
Entity public float			$ 3,384,058
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Shell Company	false
Entity Ex-Transition Period	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Current assets:
Cash	$ 131,472	$ 116,994
Total current assets	131,472	116,994
Total assets	131,472	116,994
Current liabilities:
Accounts payable and accrued expense	525,636	203,373
Due related parties	88,000
Total current liabilities	613,636	203,373
Total liabilities	613,636	203,373
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 authorized, none issued and outstanding
Common stock, $0.001 par value, 100,000,000 authorized, 32,646,635 and 27,753,365 issued and outstanding, respectively	32,647	27,754
Additional paid-in capital	12,318,685	11,350,456
Accumulated deficit	(12,833,496)	(11,464,589)
Total stockholders’ equity (deficit)	(482,164)	(86,379)
Total liabilities and stockholders’ equity	$ 131,472	$ 116,994

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2019	Mar. 31, 2018
Stockholders' deficit:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized shares	10,000,000	10,000,000
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized shares	100,000,000	100,000,000
Common stock, issued shares	32,646,635	27,753,365
Common stock, outstanding shares	32,646,635	27,753,365

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Consolidated Statements Of Operations
Revenue
Operating expenses:
General and administrative expense	1,114,942	1,027,141
Research and development	254,006	1,194,629
Income (loss) from operations	(1,368,948)	(2,221,770)
Other income (expense):
Interest income	41	125
Gain on change in fair value of derivative liabilities		346
Total other expense	41	471
Net income (loss) before income tax	(1,368,907)	(2,221,299)
Income tax
Net income (loss)	$ (1,368,907)	$ (2,221,299)
Net income (loss) per share, basic and diluted	$ (0.05)	$ (0.09)
Weighted average number of shares outstanding, basic and diluted	30,090,416	25,883,774

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, shares at Mar. 31, 2017	23,292,298
Beginning balance, amount at Mar. 31, 2017	$ 23,292	$ 9,953,759	$ (9,243,290)	$ 733,761
Common stock and warrants issued for cash, shares	3,331,598
Common stock and warrants issued for cash, amount	$ 3,332	1,162,731		1,166,063
Common stock issued to related parties for service, shares	570,108
Common stock issued to related parties for service, amount	$ 570	141,545		142,115
Common stock issued for warrant exercise, shares	514,361
Common stock issued for warrant exercise, amount	$ 515	44,991		45,506
Common stock issued for service, shares	45,000
Common stock issued for service, amount	$ 45	7,275		7,320
Option expense		40,155		40,155
Net loss			(2,221,299)	(2,221,299)
Ending Balance, Shares at Mar. 31, 2018	27,753,365
Ending Balance, Amount at Mar. 31, 2018	$ 27,754	11,350,456	(11,464,589)	(86,379)
Common stock issued for cash, shares	2,277,142
Common stock issued for cash, amount	$ 2,277	640,723		643,000
Common stock issued to related parties for service, shares	600,418
Common stock issued to related parties for service, amount	$ 600	129,936		130,536
Common stock issued for warrant exercise, shares	1,665,710
Common stock issued for warrant exercise, amount	$ 1,666	81,620		83,286
Common stock issued for service, shares	350,000
Common stock issued for service, amount	$ 350	77,550		77,550
Option expense		38,400		38,400
Net loss			(1,368,907)	(1,368,907)
Ending Balance, Shares at Mar. 31, 2019	32,646,635
Ending Balance, Amount at Mar. 31, 2019	$ 32,647	$ 12,318,685	$ (12,833,496)	$ (482,164)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (1,368,907)	$ (2,221,299)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	208,436	149,435
Option expense	38,400	40,155
Change in fair value of derivative liabilities		(346)
Changes in operating assets and liabilities:
Material held for research and development with alternative future use		769,954
Accounts payable and accrued expenses	322,263	51,720
License agreement liability		(14,000)
Due to related parties	88,000
Net cash used in operating activities	(711,808)	(1,224,381)
Cash flows from financing activities:
Proceeds from sale of common stock and warrants	643,000	1,166,063
Common stock issued for warrants exercised	83,286	45,506
Net cash provided by financing activities	726,286	1,211,569
Net increase (decrease) in cash	14,478	(12,812)
Cash – beginning of year	116,994	129,806
Cash – end of year	131,472	116,994
SUPPLEMENT DISCLOSURES:
Interest paid
Income taxes paid

ORGANIZATION AND NATURE OF OPER

ORGANIZATION AND NATURE OF OPERATIONS	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS	Nascent Biotech, Inc (“Nascent “the Company”) was incorporated on March 3, 2014 under the laws of the State of Nevada. On July 15, 2014 Biotech entered into a reverse merger with Jin-En Group International Holding Company (Jin-En). Jin-En issued 7,500,200 shares of its common stock for all the outstanding shares of Nascent Biotech, Inc. In addition, Jin-En cancelled 15,000,000 shares of its common stock. Prior to the merger Jin-En had 22,829,400 shares outstanding. Jin-En changed its name to Nascent Biotech, Inc. Jin-En had $19,000 of net liabilities at the date of the merger. The net liabilities of Jin-En consisted of the following as of the date of the merger: Receivable from Biotech $ 60,000 Accounts payable (19,000 ) Convertible note (60,000 ) Net liabilities $ (19,000 ) The Company is actively developing its primary asset Pritumumab for the treatment of brain cancer and pancreatic cancer. Nascent is also actively researching other cancers that have a high probability of benefiting from the therapeutic effects of Pritumumab because they share a common target. Pritumumab has shown to be very effective at low doses in previous clinical studies in Japan. Nascent is a clinical stage biopharmaceutical company that focuses on biologic drug candidates that are preparing for initial clinical testing for the treatment of brain and pancreatic cancer. The Company plans to open Phase 1 clinical studies during the third quarter of the calendar year.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a fiscal year ending on March 31. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Nascent Biotech, Inc. and its wholly-owned subsidiary Nascent Biologics, Inc. All intercompany accounts and transactions have been eliminated. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company as of March31, 2019 did not have any cash equivalents. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Stock-Based Compensation The Company accounts for stock-based compensation to employees and consultants in accordance with FASB ASC 718. Stock-based compensation to employees is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite employee service period. The Company accounts for stock-based compensation to other than employees in accordance with FASB ASC 505-50. Equity instruments issued to other than employees are valued at the earlier of a commitment date or upon completion of the services, based on the fair value of the equity instruments and is recognized as expense over the service period. The Company estimates the fair value of stock-based payments using the Black Scholes option-pricing model for common stock options and warrants and the closing price of the Company’s common stock for common share issuances. Research and Development Expense Research and development costs are expensed in the period they are incurred in accordance with ASC 730, Research and Development unless they meet specific criteria related to technical, market and financial feasibility, as determined by management, including but not limited to the establishment of a clearly defined future alternative use for the product, and the availability of adequate resources to complete the project. If all criteria are met, the costs are deferred and amortized over the expected useful life of the project, or expensed as research and development as the material are consumed, or written off if a product is abandoned. At March 31, 2019 and 2018, the Company had zero capitalized associated with materials held with a future alternative use. The cost of these materials is to be expensed as research and development as the materials are consumed or designated for usage. As the Company is preparing to begin clinical studies using a dose escalation method, it is not feasible to determine if the additional product will be needed for the brain cancer studies. The Company expensed the balance of the product in inventory on March 31, 2018. As of March 31, 2019 the Company no inventory value on the balance sheet. Materials Held for Research and Development with Future Alternative Use The Company has incurred costs related to the production of 424 grams of Pritumumab a human mono-clinical antibody. Of the 424 grams, the materials designated for use in the brain cancer clinical trials have been expensed as of March 31, 2017 as research and development. The Company has determined the Pritumumab can be used in its current state in pancreatic, breast and lung cancer trials, none of which have commenced. Under the guidelines of ASC 730-10-25-2, Research and Development Property and Equipment Property and equipment is recorded at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the expected useful life of the asset (3 to 5 years), beginning when the asset is available and ready for use. Expenditures associated with upgrades and enhancements that improve, add functionality, or otherwise extend the life of property and equipment are capitalized, while expenditures that do not, such as repairs and maintenance, are expensed as incurred. For the years ended March 31, 2019 and 2018, depreciation expense totaled zero, respectively. Impairment of Long-Lived Assets The Company reviews the carrying value of its long-lived assets annually or whenever events or changes in circumstances indicate that the historical-cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset. Fair value is estimated based upon either discounted cash flow analysis or estimated salvage value. There was no impairment recognized during the years ended March 31, 2019 and 2018. Income Taxes Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company accounts for income taxes under the provisions of FASB ASC 740, Accounting for Income Taxes Basic and Diluted Net Income (Loss) per Share Basic net income (loss) per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the year. During the year ended March 31, 2019 the Company had a net loss so the options and warrants outstanding were not part the loss per share calculation as they would be antidilutive. Diluted income (loss) per share calculations includes the dilutive effect of warrants and options on the weighted average of the per share calculation. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Financial assets and liabilities recorded at fair value in our condensed consolidated balance sheets are categorized based upon a fair value hierarchy established by GAAP, which prioritizes the inputs used to measure fair value into the following levels: Level 1— Quoted market prices in active markets for identical assets or liabilities at the measurement date. Level 2— Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data. Level 3— Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the instruments. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. On May 20, 2014 the Company granted 13,317 common stock warrants for services. The warrants vest immediately, are exercisable at $1.00 per share and expire on May 21, 2017. The Company determined that the warrants were not afforded equity classification because the warrants are not considered to be indexed to the Company’s own stock due to the anti-dilution provision. Accordingly, the warrants are treated as a derivative liability and are carried at fair value. The Company estimated the fair value of these derivative warrants at each balance sheet date and the changes in fair value are recognized in earnings in the statement of operations under the caption “gain (loss) on change in fair value of derivative liability” until such time as the derivative warrants are exercised or expire. The Company used the Black-Scholes Option Pricing model to estimate the fair value of the derivative liability as of the date of issuance and as of March 31, 2017 using the following key inputs: market price of the Company’s common stock $0.10 to $1.51 per share in 2016 and $0.40 in 2017, volatility of 250% and discount rate of 0.13%. The fair value of the derivative liability was determined to be zero as of March 31, 2018 and due to the expiration of the warrants the ending balance of the derivative liability was zero as of March 31, 2018 and 2019. The following table summarizes the change in the fair value of the derivative liabilities during the years ended March 31, 2019 and 2018: Fair value as of March 31, 2017 346 Additions at fair value -- Transfers in (out) of Level 3 -- Change in fair value (346 ) Fair value as of March 31, 2018 $ -- Additions at fair value -- Transfers in (out) of Level 3 -- Change in fair value -- Fair value as of March 31, 2019 $ -- Recent Accounting Pronouncements Stock-Based Compensation The Company accounts for stock-based compensation to employees and consultants in accordance with FASB ASC 718. Stock-based compensation to employees is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite employee service period. The Company accounts for stock-based compensation to other than employees in accordance with FASB ASC 505-50. Equity instruments issued to other than employees are valued at the earlier of a commitment date or upon completion of the services, based on the fair value of the equity instruments and is recognized as expense over the service period. The Company estimates the fair value of stock-based payments using the Black Scholes option-pricing model for common stock options and warrants and the closing price of the Company’s common stock for common share issuances.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
NOTE 3 - GOING CONCERN	The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company, as shown in the accompanying consolidated balance sheets, has working capital deficit of $482,164 and an accumulated deficit of $12,833,496 as of March 31, 2019. The Company does not have a source of revenue to cover its operating costs. These factors raise substantial doubt about the company’s ability to continue as a going concern. The Company will engage in research and development activities that must be satisfied in cash secured through outside funding. The Company will offer noncash consideration and seek equity lines as a means of financing its operations. If the Company is unable to obtain revenue producing contracts or financing or if the revenue or financing it does obtain is insufficient to cover any operating losses it may incur, it may substantially curtail or terminate its operations or seek other business opportunities through strategic alliances, acquisitions or other arrangements that may dilute the interests of existing stockholders.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
NOTE 4 - RELATED PARTY TRANSACTIONS	On September 1, 2015, the Company entered into five year employment contracts with three of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company as of the date of the contracts. As additional future shares are issued, the officers and directors are entitled to additional shares, so their aggregate ownership percentage remains at 11% of the outstanding shares of the Company. The following table sets forth the shares earned under these contracts from inception through year ended March 31, 2019: Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 629,034 1,657,944 Chief Financial Officer 617,346 380,228 997,574 Executive Vice President 617,346 380,228 997,574 Total 2,263,602 1,389,668 3,653,092 In addition, if the officers and directors are removed from the Company, they are entitled to receive a cash severance payment per annum for each year of the term of the contract less salary payments received to date of termination. The table below sets forth the annual salary and annual severance amounts per the contracts: Officer and Director Annual Compensation Paid for Fiscal Year Annual Severance per Contract if Terminated President $ 186,000 $ 250,000 Chief Financial Officer (1) $ 132,000 $ 180,000 Executive Vice President(2) $ 84,000 $ 140,000 Total $ 402,000 $ 570,000 _______ (1) The Chief Financial Officers was paid $101,000 in cash and accrued $31,000 in fees (2) The Executive Vice President was paid $34,000 in cash and accrued $50,000 in fees During the year ended March 31, 2018, the Company issued 520,108 shares of common stock to three officers with a fair value of $131,115 for services and compensation. During the years ended March 31, 2019, the Company paid a consultant and former officer of the Company $23,000 and accrued $7,000 and in 2018 $60,000 in consulting fees. During the year ended March 31, 2018, the Company issued 50,000 shares of common stock to a director with a fair value of $11,000. During the year ended March 31, 2019, the Company issued 600,418 shares of common stock to three officers with a fair value of $130,536 for services and compensation

LICENSE SETTLEMENT

LICENSE SETTLEMENT	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
NOTE 5 - – LICENSE SETTLEMENT	On October 12, 2017 the Company signed a consulting agreement with a former license holder. Under the terms of the agreement the Company, commencing February 1, 2018 will pay the consultant $1,000 per month for 24 months. In addition, the Company will pay the consultant an additional $24,000 during the term of the agreement at the Company’s discretion. In return, the consultant will forgive all royalty payments plus any past claims to the product per the previous agreement dated September 21, 2015, plus provide consulting services to the Company as directed by the Company. As of March 31, 2019 the consultant’s agreement entitles the consultant to $34,000throught February28, 2020.

COMMON STOCK

COMMON STOCK	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
NOTE 6 - COMMON STOCK	During the year ended March 31, 2018, the Company issued, 3,331,598 shares of common stock at $0.35 per share and 1,665,566 warrants exercisable at $0.05 to $0.10 per share to 17 individuals for $1,166,063 of cash. During the year ended March 31, 2018 the Company issued 514,361 shares of common stock to 11 individuals on the exercise of 514,361 warrants for cash. During the year ended March 31, 2018 the Company issued 520,108 shares of common stock to three officers and with a fair value of $131,115 for services and compensation. During the year ended March 31, 2018 the Company issued 50,000 shares of common stock to an independent director with a fair value of $11,000 for services. During the year ended March 31, 2018 the Company issued 45,000 shares of common stock to 3 individuals with a value of $7,320 for service. During the year ended March 31, 2019 the Company issued 1,277,142 shares of common stock to 15 individuals plus 237,747 warrants to eight individuals for $393,000 in cash. The warrants vest immediately and terminate in one year with conversion prices ranging from $0.05-$0.50. During the year ended March 31, 2019 the Company issued 1,000,000 shares of common stock to one individual for cash of $250,000. During year ended March 31, 2019 the Company issued 1,665,710 shares of common stock for the exercise of 1,665,710 warrants for cash of $83,286. During the year ended March 31, 2019 the Company issued 350,000 shares of common stock of the Company to six individuals with a value of $77,900 for service. During the year ended March 31, 2019 the Company issued 600,418 shares of common stock to three officers of the Company with a value of $130,536 for service.

OPTIONS

OPTIONS	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
NOTE 7 - OPTIONS	The Company under its 2015 option plan issues options to various officers, directors and consultants. The options vest in equal annual installments over a five year period with the first 20% vested when the options were granted. All of the options are exercisable at a purchase price based on the last trading price of the Company’s common stock on the date of grant and have a term of 10 years. On April 1, 2016, the Company issued 40,000 options to a consultant under the 2015 option program. The options are exercisable into the Company’s common stock at $0.30 per share, have term of 10 years and vest in 5 equal annual installments with the first installment vesting on the date of grant. This award to a nonemployee is revalued at each reporting period until completion of services. On April 1, 2016, the Company entered a consulting agreement under which the consultant was granted 30,000 options on April 1, 2016. In addition, the consultant received additional option grants of 30,000 options on April 1, 2017 and 40,000 options on April 1, 2018. The options are exercisable into the Company’s common stock at $0.30 per share, have term of 10 years and vest in 5 equal annual installments with the first installment vesting on the date of grant. On July 20, 2016, the Company granted from the 2015 Option Program 300,000 options each to three officers and directors for a total of 900,000 options being granted. The options are exercisable into the Company’s common stock at an exercise price of $0.301 per share and were vested and expensed at the date of issuance. The fair value at date of granted was determined to be $484,205. On April 1, 2018, the Company granted from the 2015 Option Program 40,000 options to one consultant. The options are exercisable into the Company’s common stock at an exercise price of $0.25 per share and were vested and expensed at the date of issuance. The fair value at date of granted was determined to be $9,991. During the years ended March 31, 2019 and 2018, the Company expensed an aggregate of $38,400 and $40,155, respectively related to its option awards. The unrecognized future balance to be expensed over the remaining vesting term of the options is $19,836 as of March 31, 2018 and $497 as of March 31, 2019. The following sets forth the options granted and outstanding during the years ended March 31, 2019 and 2018: Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2017 1,365,000 $ 0.35 8.88 1,143,000 $ 36,000 Granted -- -- -- -- -- Exercised -- -- -- -- -- Outstanding at March 31, 2018 1,365,000 $ 0.35 7.88 1,236,000 $ -- Granted 40,000 0.25 9.00 16,000 -- Exercised -- -- -- -- -- Outstanding at March 31, 2019 1,405,000 $ 0.34 6.80 1,397,000 $ --

WARRANTS

WARRANTS	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
NOTE 8 - WARRANTS	During the year ended March 31, 2018, the Company issued 274,228 warrants, each warrant is exercisable, within one year of the issuance, into one share of the Company’s common stock at $0.35 per share. The warrants were issued as commission of equity financing and is regarded as stock issuance cost and a reduction to cash proceeds. (See Note 6: Common Stock) The warrants were priced using the Black Scholes method measuring at date of issuance with a discount rate of .96%, volatility of 191.95 and measurement price of $0.20 with a fair value of $48,069. During the year ended March 31, 2018 the Company issued 1,665,566 warrants to 17 shareholders along with 3,331,598 common shares for aggregate cash proceeds of $1,166,063. Each warrant is exercisable within one year of the issuance date into one share of the Company’s common stock at $0.05-0.10 per share. As of March 31, 2018, 514,361 warrants, were exercised, 13,317 expired, leaving a balance outstanding of 1,939,794. During the year ended March 31, 2019, the Company issued 237,747 warrants for cash proceeds (Note 6). Each warrant is exercisable, within one year of the issuance, into one share of the Company’s common stock at $0.05 to $0.50 per share. During the year ended March 31, 2019 seventeen individuals exercised 1,665,710 warrants into 1,665,710 shares of common stock for cash of $83,286. As of March 31, 2019, the Company had total outstanding warrants of 237,747. During the year ended March 31, 2019, 274,084 warrants expired. The weighted average remaining life and intrinsic value of the warrants as of March 31, 2019, was 0.20 years and zero, respectively. Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2017 527,678 $ 0.11 .84 $ 128,661 Granted 1,939,794 0.10 -- -- Expired (13,317 ) 1.00 Exercised (514,361 ) 0.09 -- -- Outstanding at March 31, 2018 1,939,794 $ 0.09 .38 $ 333,133 Granted 237,747 0.20 .87 -- Expired (274,084 ) (0.35 ) -- -- Exercised (1,665,710 ) 0.05 -- -- Outstanding at March 31, 2019 237,747 $ 0.20 .25 $ 18,470 As of March 31, 2019 the outstanding exercisable options were 237,747 with expiration dates from March 26, 2019 to July 10, 2019.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
NOTE 9 - – INCOME TAXES	At March 31, 2019 and 2018, the Company had federal net operating loss carry forwards of approximately $8,395,599 and $7,274,992, respectively, which expire in varying amounts beginning in 2029. Components of net deferred tax assets, including a valuation allowance, are as follows at March 31, 2019 and 2018: March 31, 2019 March 31, 2018 Deferred tax assets: Net operating loss $ 1,763,076 $ 1,527,748 Less: Valuation allowance (1,763,076 ) (1,527,748 ) Net deferred tax assets $ -- $ -- In assessing the recovery of the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in the periods in which those temporary differences become deductible. Management considers the scheduled reversals of future deferred tax assets, projected future taxable income, and tax planning strategies in making this assessment. As a result, management determined it was more likely than not the deferred tax assets would not be realized as of March 31, 2019. Based on the recent change in corporation tax rates the Company calculated the deferred tax asset for the years ended March 31, 2019 and 2018 at 21%. The parent Company due to its loses has not filed US Corporate tax returns and is subject to examination back to March 31, 2015.

MATERIALS HELD FOR RESEARCH AND

MATERIALS HELD FOR RESEARCH AND DEVELOPMENT WITH ALTERNATIVE FUTURE ALTERNATIVE USE	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
NOTE 10 - – MATERIALS HELD FOR RESEARCH AND DEVELOPMENT WITH ALTERNATIVE FUTURE ALTERNATIVE USE	During the year ended March 31, 2015, the Company, through contract manufacturing incurred costs related to the production of 424 grams of Pritumumab (bulk drug substance), a human monoclonal antibody. The product is being produced for use in research and development. In addition to the use in the brain cancer clinical trials, the Company has also determined the Pritumumab can be used in its current state for pancreatic, breast and lung cancer trials, none of which have commenced. Due to the existence of these alternative future uses, the Company has capitalized the cost of these materials not expected to be used in the brain cancer trials. Of the 424 grams being produced, cost of the grams initially expected to be used in the brain cancer trials was expensed as research and development during the year ended March 31, 2015. The amount capitalized by the Company as of March 31, 2016 was $788,412. These capitalized costs will be expensed as research and development as the materials are consumed. During the year ended March 31, 2017, an additional $58,010 was expensed as research and development associated with the portion filled into vials for use in clinical trials leaving. The Company expensed during the year ended March 31, 2018 an additional $234,334 for the additional portion used in the fill and finish which was used for testing and in preparation for clinical trials in brain cancer. As the Company will begin clinical studies using a dose escalation method, it is not feasible to determine if the additional product will be needed for the brain cancer studies the Company expensed the balance of the product in inventory on March 31, 2018. As of March 31, 2019 the product carries no value on the consolidated balance sheet of the Company.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
NOTE 11 - COMMITMENTS AND CONTINGENCIES	On June 30, 2016 the Company entered into a cell line sales agreement with the product manufacture. Under the terms of the agreement the company is obligated to make future payments based on the milestones of its achievements. These future payments may be as followed; 1. $100,000 upon the initiation (first dose/first patient) of the first Phase I clinical trial (or equivalent) of a product; 2. $225,000 upon the initiation (first dose/first patient) of the first Phase III clinical trial (or equivalent) of a product 3. $225,000 payable upon the first BLA approval (or equivalent) of a product. 4. Annual maintenance fee upon completion of phase I manufacturing or the transfer of the cell line from Catalent’s control of $50,000; 5. A contingent sales fee upon product sales of 1% of sales or $150,000 whichever is greater.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
NOTE 12 - SUBSEQUENT EVENTS	On June 5, 2019, two officers and directors of the Company converted $99,000 of accrued fees into 639,536 shares of common stock at $0.1548 per share. During June 2019, two warrant holders exercised 21,427 warrants for common stock at $0.05 per share with a value of $1,072. On June 14, 2019 the Company issued 50,000 share of common stock to one individual with a value of $9,550 for service. On June 28, 2019 the Company issued 137,872 shares of common stock to three officers and a director for service with a value of $25,786. On July 10, 2019 the Company filed an amended articles of Incorporation designating 1,.500,000 shares of preferred stock as Series A Convertible preferred shares convertible into common stock.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Mar. 31, 2019
Significant Accounting Policies
Basis of Presentation	The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a fiscal year ending on March 31.
Principles of Consolidation	The accompanying consolidated financial statements include the accounts of Nascent Biotech, Inc. and its wholly-owned subsidiary Nascent Biologics, Inc. All intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company as of March31, 2019 did not have any cash equivalents.
Use of Estimates	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.
Stock-Based Compensation	The Company accounts for stock-based compensation to employees and consultants in accordance with FASB ASC 718. Stock-based compensation to employees is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite employee service period. The Company accounts for stock-based compensation to other than employees in accordance with FASB ASC 505-50. Equity instruments issued to other than employees are valued at the earlier of a commitment date or upon completion of the services, based on the fair value of the equity instruments and is recognized as expense over the service period. The Company estimates the fair value of stock-based payments using the Black Scholes option-pricing model for common stock options and warrants and the closing price of the Company’s common stock for common share issuances.
Research and Development Expense	Research and development costs are expensed in the period they are incurred in accordance with ASC 730, Research and Development unless they meet specific criteria related to technical, market and financial feasibility, as determined by management, including but not limited to the establishment of a clearly defined future alternative use for the product, and the availability of adequate resources to complete the project. If all criteria are met, the costs are deferred and amortized over the expected useful life of the project, or expensed as research and development as the material are consumed, or written off if a product is abandoned. At March 31, 2019 and 2018, the Company had zero capitalized associated with materials held with a future alternative use. The cost of these materials is to be expensed as research and development as the materials are consumed or designated for usage. As the Company is preparing to begin clinical studies using a dose escalation method, it is not feasible to determine if the additional product will be needed for the brain cancer studies. The Company expensed the balance of the product in inventory on March 31, 2018. As of March 31, 2019 the Company no inventory value on the balance sheet.
Materials Held for Research and Development with Future Alternative Use	The Company has incurred costs related to the production of 424 grams of Pritumumab a human mono-clinical antibody. Of the 424 grams, the materials designated for use in the brain cancer clinical trials have been expensed as of March 31, 2017 as research and development. The Company has determined the Pritumumab can be used in its current state in pancreatic, breast and lung cancer trials, none of which have commenced. Under the guidelines of ASC 730-10-25-2, Research and Development
Property and Equipment	Property and equipment is recorded at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the expected useful life of the asset (3 to 5 years), beginning when the asset is available and ready for use. Expenditures associated with upgrades and enhancements that improve, add functionality, or otherwise extend the life of property and equipment are capitalized, while expenditures that do not, such as repairs and maintenance, are expensed as incurred. For the years ended March 31, 2019 and 2018, depreciation expense totaled zero, respectively.
Impairment of Long-Lived Assets	The Company reviews the carrying value of its long-lived assets annually or whenever events or changes in circumstances indicate that the historical-cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset. Fair value is estimated based upon either discounted cash flow analysis or estimated salvage value. There was no impairment recognized during the years ended March 31, 2019 and 2018.
Income Taxes	At March 31, 2019 and 2018, the Company had federal net operating loss carry forwards of approximately $8,395,599 and $7,274,992, respectively, which expire in varying amounts beginning in 2029. Components of net deferred tax assets, including a valuation allowance, are as follows at March 31, 2019 and 2018: March 31, 2019 March 31, 2018 Deferred tax assets: Net operating loss $ 1,763,076 $ 1,527,748 Less: Valuation allowance (1,763,076 ) (1,527,748 ) Net deferred tax assets $ -- $ -- In assessing the recovery of the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in the periods in which those temporary differences become deductible. Management considers the scheduled reversals of future deferred tax assets, projected future taxable income, and tax planning strategies in making this assessment. As a result, management determined it was more likely than not the deferred tax assets would not be realized as of March 31, 2019. Based on the recent change in corporation tax rates the Company calculated the deferred tax asset for the years ended March 31, 2019 and 2018 at 21%. The parent Company due to its loses has not filed US Corporate tax returns and is subject to examination back to March 31, 2015.
Basic and Diluted Net Income (Loss) per Share	Basic net income (loss) per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the year. During the year ended March 31, 2019 the Company had a net loss so the options and warrants outstanding were not part the loss per share calculation as they would be antidilutive. Diluted income (loss) per share calculations includes the dilutive effect of warrants and options on the weighted average of the per share calculation.
Fair Value of Financial Instruments	The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Financial assets and liabilities recorded at fair value in our condensed consolidated balance sheets are categorized based upon a fair value hierarchy established by GAAP, which prioritizes the inputs used to measure fair value into the following levels: Level 1— Quoted market prices in active markets for identical assets or liabilities at the measurement date. Level 2— Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data. Level 3— Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the instruments. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. On May 20, 2014 the Company granted 13,317 common stock warrants for services. The warrants vest immediately, are exercisable at $1.00 per share and expire on May 21, 2017. The Company determined that the warrants were not afforded equity classification because the warrants are not considered to be indexed to the Company’s own stock due to the anti-dilution provision. Accordingly, the warrants are treated as a derivative liability and are carried at fair value. The Company estimated the fair value of these derivative warrants at each balance sheet date and the changes in fair value are recognized in earnings in the statement of operations under the caption “gain (loss) on change in fair value of derivative liability” until such time as the derivative warrants are exercised or expire. The Company used the Black-Scholes Option Pricing model to estimate the fair value of the derivative liability as of the date of issuance and as of March 31, 2017 using the following key inputs: market price of the Company’s common stock $0.10 to $1.51 per share in 2016 and $0.40 in 2017, volatility of 250% and discount rate of 0.13%. The fair value of the derivative liability was determined to be zero as of March 31, 2018 and due to the expiration of the warrants the ending balance of the derivative liability was zero as of March 31, 2018 and 2019. The following table summarizes the change in the fair value of the derivative liabilities during the years ended March 31, 2019 and 2018: Fair value as of March 31, 2017 346 Additions at fair value -- Transfers in (out) of Level 3 -- Change in fair value (346 ) Fair value as of March 31, 2018 $ -- Additions at fair value -- Transfers in (out) of Level 3 -- Change in fair value -- Fair value as of March 31, 2019 $ --
Recent Accounting Pronouncements	Stock-Based Compensation The Company accounts for stock-based compensation to employees and consultants in accordance with FASB ASC 718. Stock-based compensation to employees is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite employee service period. The Company accounts for stock-based compensation to other than employees in accordance with FASB ASC 505-50. Equity instruments issued to other than employees are valued at the earlier of a commitment date or upon completion of the services, based on the fair value of the equity instruments and is recognized as expense over the service period. The Company estimates the fair value of stock-based payments using the Black Scholes option-pricing model for common stock options and warrants and the closing price of the Company’s common stock for common share issuances.

ORGANIZATION AND NATURE OF OP_2

ORGANIZATION AND NATURE OF OPERATIONS (Tables)	12 Months Ended
	Mar. 31, 2019
Organization And Nature Of Operations
Schedule net liabilities of Jin-En	Receivable from Biotech $ 60,000 Accounts payable (19,000 ) Convertible note (60,000 ) Net liabilities $ (19,000 )

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2019
Significant Accounting Policies Tables Abstract
summarizes of change in the fair value of the derivative liabilities	Fair value as of March 31, 2017 346 Additions at fair value -- Transfers in (out) of Level 3 -- Change in fair value (346 ) Fair value as of March 31, 2018 $ -- Additions at fair value -- Transfers in (out) of Level 3 -- Change in fair value -- Fair value as of March 31, 2019 $ --

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Mar. 31, 2019
Related Party Transactions
Contracts shares earned	Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 629,034 1,657,944 Chief Financial Officer 617,346 380,228 997,574 Executive Vice President 617,346 380,228 997,574 Total 2,263,602 1,389,668 3,653,092
Annual salary and annual severance amounts per the contracts of related party	Officer and Director Annual Compensation Paid for Fiscal Year Annual Severance per Contract if Terminated President $ 186,000 $ 250,000 Chief Financial Officer (1) $ 132,000 $ 180,000 Executive Vice President(2) $ 84,000 $ 140,000 Total $ 402,000 $ 570,000

OPTIONS (Tables)

OPTIONS (Tables)	12 Months Ended
	Mar. 31, 2019
Option [Member]
Summary of stock options and warrants outstanding	Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2017 1,365,000 $ 0.35 8.88 1,143,000 $ 36,000 Granted -- -- -- -- -- Exercised -- -- -- -- -- Outstanding at March 31, 2018 1,365,000 $ 0.35 7.88 1,236,000 $ -- Granted 40,000 0.25 9.00 16,000 -- Exercised -- -- -- -- -- Outstanding at March 31, 2019 1,405,000 $ 0.34 6.80 1,397,000 $ --

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Mar. 31, 2019
Warrant [Member]
Summary of stock options and warrants outstanding	Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2017 527,678 $ 0.11 .84 $ 128,661 Granted 1,939,794 0.10 -- -- Expired (13,317 ) 1.00 Exercised (514,361 ) 0.09 -- -- Outstanding at March 31, 2018 1,939,794 $ 0.09 .38 $ 333,133 Granted 237,747 0.20 .87 -- Expired (274,084 ) (0.35 ) -- -- Exercised (1,665,710 ) 0.05 -- -- Outstanding at March 31, 2019 237,747 $ 0.20 .25 $ 18,470

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2019
Income Taxes
Summary of net deferred tax assets	March 31, 2019 March 31, 2018 Deferred tax assets: Net operating loss $ 1,763,076 $ 1,527,748 Less: Valuation allowance (1,763,076 ) (1,527,748 ) Net deferred tax assets $ -- $ --

ORGANIZATION AND NATURE OF OP_3

ORGANIZATION AND NATURE OF OPERATIONS (Details) - Jin-En Group International Holding Company [Member] - USD ($)	Mar. 31, 2019	Jul. 15, 2014
Receivable from Biotech	$ 60,000
Accounts payable	(19,000)
Convertible note	(60,000)
Net liabilities	$ (19,000)	$ 19,000

ORGANIZATION AND NATURE OF OP_4

ORGANIZATION AND NATURE OF OPERATIONS (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Jul. 15, 2014
Date of Incorporation	Mar. 3, 2014
State of Incorporation	Nevada
Common stock outstanding shares	32,646,635	27,753,365
Jin-En Group International Holding Company [Member]
Common stock, issued shares			7,500,200
Common stock cancelled shares			15,000,000
Common stock outstanding shares			22,829,400
Net liabilities	$ (19,000)		$ 19,000

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Significant Accounting Policies Detail 1Abstract
Begnning Balance		$ 346
Additions at fair value
Transfers in (out) of Level 3
Change in fair value		(346)
Ending Balance

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	May 20, 2014	Mar. 31, 2019	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2016
Common stock warrants for services	13,317
Warrant vested to exercisable price	$ 1
Date of expired	May 21, 2017
Stock per share			$ 0.40
Fair value of derivative liability			$ 346
Discount rate			0.13%
Volatility rate			250.00%
Minimum [Member]
Property and equipment useful life		3 years
Stock per share					$ 0.10
Maximum [Member]
Property and equipment useful life		5 years
Stock per share					$ 1.51

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Going Concern
Working capital deficit	$ (482,164)
Accumulated Deficit	$ (12,833,496)	$ (11,464,589)

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	12 Months Ended
	Mar. 31, 2019shares
Initial Share Awards Under the Contracts	2,263,602
Additional Shares Earned to Maintain Ownership Percentage	1,389,668
Total Shares Earned	3,653,092
President [Member]
Initial Share Awards Under the Contracts	1,028,910
Additional Shares Earned to Maintain Ownership Percentage	629,034
Total Shares Earned	1,657,944
Chief Financial Officer [Member]
Initial Share Awards Under the Contracts	617,346
Additional Shares Earned to Maintain Ownership Percentage	380,228
Total Shares Earned	997,574
Executive Vice President [Member]
Initial Share Awards Under the Contracts	617,346
Additional Shares Earned to Maintain Ownership Percentage	380,228
Total Shares Earned	997,574

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details 1)	12 Months Ended
	Mar. 31, 2019USD ($)
Fiscal year annualized compensation being paid	$ 402,000
Annual Severance per Contract if Terminated	570,000
President [Member]
Fiscal year annualized compensation being paid	186,000
Annual Severance per Contract if Terminated	250,000
Chief Financial Officer [Member]
Fiscal year annualized compensation being paid	132,000	[1]
Annual Severance per Contract if Terminated	180,000	[1]
Executive Vice President [Member]
Fiscal year annualized compensation being paid	84,000	[2]
Annual Severance per Contract if Terminated	$ 140,000	[2]
[1]	The Chief Financial Officers was paid $101,000 in cash and accrued $31,000 in fees
[2]	The Executive Vice President was paid $34,000 in cash and accrued $50,000 in fees

RELATED PARTY TRANSACTIONS (D_3

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Chief Financial Officer [Member]
Fiscal year annualized compensation being paid	$ 101,000
Accrued annualized compensation being paid	31,000
Executive Vice President [Member]
Fiscal year annualized compensation being paid	34,000
Accrued annualized compensation being paid	50,000
Former Officer [Member]
Consulting fees	$ 60,000	$ 23,000
Accrued consulting fees		$ 7,000
Three Officers And Director [Member]
Common shares issued	50,000
Common shares issued for services, fair value	$ 11,000
Three Officers And Director [Member] | September 1, 2015 [Member]
Officers and directors employment agreement terms, description	The Company entered into five year employment contracts with three of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company as of the date of the contracts. As additional future shares are issued, the officers and directors are entitled to additional shares, so their aggregate ownership percentage remains at 11% of the outstanding shares of the Company
Three Officers [Member]
Consulting fees	$ 60,000
Common shares issued	600,418	520,108
Common shares issued for services, fair value	$ 130,536	$ 131,115

LICENSE SETTLEMENT (Details Nar

LICENSE SETTLEMENT (Details Narrative) - Consulting agreement [Member]	Oct. 12, 2017USD ($)	Mar. 31, 2019USD ($)
Number of installments, consideration for license	24
Monthly installment payment	$ 1,000
Consulting fees payable	$ 24,000
Consulting fees		$ 34,000

COMMON STOCK (Details Narrative

COMMON STOCK (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Warrants Exercised		195,000
Common share value for services	$ 77,550	$ 7,320
Common stock and warrants issued for cash, Amount		$ 1,166,063
Warrant [Member]
Warrants Exercised	1,665,710	(514,361)
Warrants granted, shares	1,665,710	1,939,794
17 Individuals [Member]
Common shares issued, shares		3,331,598
Exercise price per share		$ 0.35
Common stock and warrants issued for cash, Amount		$ 1,166,063
17 Individuals [Member] | Warrant [Member]
Number of exercisable shares		1,665,566
17 Individuals [Member] | Warrant [Member] | Minimum [Member]
Exercise price per share		$ 0.05
17 Individuals [Member] | Warrant [Member] | Maximum [Member]
Exercise price per share		$ 0.10
11 Individuals [Member]
Common stock and warrants issued for cash, Shares		514,361
Three Individuals [Member]
Common share issued for services		45,000
Common share value for services		$ 7,320
Independent Director [Member]
Common share issued for services		50,000
Common share value for services		$ 11,000
Three Officers [Member]
Common share issued for services	600,418	520,108
Common share value for services	$ 130,536	$ 131,115
Six Individuals [Member]
Common share issued for services	350,000
Common share value for services	$ 77,900
Fifteen Individuals [Member]
Common shares issued, shares	1,277,142
Common shares issued, amount	$ 393,000
Warrants granted, shares	237,747
Common stock description	The warrants vest immediately and terminate in one year with conversion price from $0.05-$0.50
Fifteen Individuals [Member] | Minimum [Member]
Conversion price	$ 0.05
Fifteen Individuals [Member] | Maximum [Member]
Conversion price	$ 0.50
One Individual [Member]
Common shares issued, shares	1,000,000
Common shares issued, amount	$ 250,000

OPTIONS (Details)

OPTIONS (Details) - Option [Member] - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Outstanding, Beginning	1,365,000	1,365,000
Option granted	40,000
Option exercised
Outstanding option, Ending	1,405,000	1,365,000
Weighted average exercise price, Beginning	$ 0.35	$ 0.35
Granted	0.25
Exercised
Weighted average exercise price, Ending	$ 0.34	$ 0.35
Weighted average remaining contract life, Beginning	7 years 10 months 17 days	8 years 10 months 17 days
Weighted average remaining contract life granted	9 years
Weighted average remaining contract life, Ending	6 years 9 months 18 days	7 years 10 months 17 days
Number of options exercisable Beginning balance	1,236,000	1,143,000
Granted	16,000
Exercised
Number of options exercisable ending balance	1,397,000	1,236,000
Intrinsic value, Beginning		$ 36,000
Granted
Exercised
Intrinsic value, Ending

OPTIONS (Details Narrative)

OPTIONS (Details Narrative)	1 Months Ended		12 Months Ended
	Apr. 02, 2018USD ($)$ / sharesshares	Jul. 20, 2016USD ($)$ / sharesshares	Mar. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2018USD ($)
Options vest period				5 years
Vest percentage at grant			20.00%
Common stock exercisable term			10 years
Option expense | $			$ 38,400	$ 40,155
Unrecognized future balance to be expensed | $			$ 497	$ 19,836
Option 2 [Member]
Issued options	40,000	300,000
Exercise price of options | $ / shares	$ 0.25	$ 0.301
Numbers of officers and directors issued		3
Fair value of option granted | $	$ 9,991	$ 484,205
Options granted		900,000
Option 1 [Member] | April 1, 2018 [Member]
Common stock exercisable term			10 years
Exercise price of options | $ / shares			$ 0.30
Number of installments vest			5
Options granted			40,000
Option 1 [Member] | April 1, 2017 [Member]
Options granted			30,000
Option 1 [Member] | April 1, 2016 [Member]
Common stock exercisable term			10 years
Issued options			40,000
Exercise price of options | $ / shares			$ 0.30
Number of installments vest			5
Options granted			30,000

WARRANTS (Details)

WARRANTS (Details) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Warrants exercised, shares		195,000
Warrant [Member]
Outstanding, Beginning	1,939,938	527,678
Warrants granted, shares	1,665,710	1,939,794
Warrants exercised, shares	1,665,710	(514,361)
Outstanding option, Ending	237,747	1,939,938
Weighted average exercise price, Beginning	$ 0.09	$ 0.11
Granted	0.20	0.10
Exercised	0.05	0.09
Expired	(0.35)	1
Weighted average exercise price, Ending	$ 0.20	$ 0.09
Weighted average remaining contract life, Beginning	4 months 17 days	10 months 3 days
Weighted average, granted	10 months 14 days
Weighted average remaining contract life, Ending	2 months 30 days
Intrinsic value, Beginning	$ 333,133	$ 128,661
Intrinsic value granted
Intrinsic value exercised
Intrinsic value expired
Intrinsic value, Ending	$ 18,470	$ 333,133

WARRANTS (Details Narrative)

WARRANTS (Details Narrative)	12 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2018USD ($)$ / sharesshares	Mar. 31, 2017USD ($)
Company issued warrants, shares		1,665,566
Number of shareholders issued warrants		17
Common shares issued for cash, shares		3,331,598
Common shares issued for cash, amount | $		$ 1,166,063
Warrants excisable period		1 year
Warrants exercised		195,000
Fair value of derivative liability | $			$ 346
Warrant [Member]
Company issued warrants, shares	237,747	274,228
Warrants excisable period	1 year	1 year
Warrants expired, shares		13,317
Warrants exercised	1,665,710	(514,361)
Warrants granted, shares	1,665,710	1,939,794
Warrants exercised value | $	$ 83,286
Outstanding	237,747
Exercise price | $ / shares		$ 0.35
Volatility rate		191.95%
Discount rate		0.96%
Measurement price | $ / shares		$ 0.20
Fair value of derivative liability | $		$ 48,069
Outstanding option, Ending	237,747	1,939,938
Expiration date	March 26, 2019 to July 10, 2019
Minimum [Member]
Warrants issued per share | $ / shares	$ 0.05	$ 0.05
Maximum [Member]
Warrants issued per share | $ / shares	$ 0.50	$ 0.10

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Deferred tax assets:
Net operating loss	$ 1,763,076	$ 1,527,748
Less: Valuation allowance	(1,763,076)	(1,527,748)
Net deferred tax assets

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Taxes Details Narrative
Federal net operating loss carry forwards	$ (8,395,599)	$ (7,274,992)
Expire year	2029
Federal tax rate	21.00%	21.00%

MATERIALS HELD FOR RESEARCH A_2

MATERIALS HELD FOR RESEARCH AND DEVELOPMENT WITH ALTERNATIVE FUTURE ALTERNATIVE USE (Details Narrative) - USD ($)	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Materials Held For Research And Development With Alternative Future Alternative Use Details Narrative
Amount capitalized for development	$ 234,334	$ 58,010	$ 788,412

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative)	1 Months Ended
	Jun. 30, 2016USD ($)
Contingent sales fee description	A contingent sales fee upon product sales of 1% of sales or $150,000 whichever is greater.
first Phase III clinical trial [Member]
Future payments	$ 225,000
first BLA [Member]
Future payments	225,000
first Phase I clinical trial [Member]
Future payments	100,000
Annual maintenance fee	$ 50,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jun. 14, 2019	Jun. 05, 2019	Jun. 30, 2019	Jun. 28, 2019	Mar. 31, 2019	Mar. 31, 2018	Jul. 10, 2019	Jun. 11, 2019
Common stock value issued for services					$ 77,550	$ 7,320
Warrants exercised						195,000
Preferred stock, authorized shares					10,000,000	10,000,000
Subsequent Event [Member]
Warrants exercised			21,427
Warrants exercised value			$ 1,072
Exercise price			$ 0.05
Subsequent Event [Member] | Series A Convertible Preferred Shares[Member]
Preferred stock, authorized shares							1,500,000
Subsequent Event [Member] | Officers And Directors [Member]
Due to related party								$ 10,000
Subsequent Event [Member] | Three Officers And Directors [Member]
Common stock shares issued for services				137,872
Common stock value issued for services				$ 25,786
Subsequent Event [Member] | One Individuals [Member]
Common stock shares issued for services	50,000
Common stock value issued for services	$ 9,550
Subsequent Event [Member] | Two Officers And Directors [Member]
Accrued fees converted amount		$ 99,000
Accrued fees converted amount, shares		639,536
Conversion price per share		$ 0.1548